Search
Quercus alba pollen
go.drugbank.com/drugs/DB10376ApprovedIt can be subcutaneously administered to initiate an immune response in case of an allergic reaction. … Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.
Products: Center-AL - Quercus Alba PollenInterleukin-7
go.drugbank.com/drugs/DB11997InvestigationalInterleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Synonyms: IL-7Pentafluoropropane
go.drugbank.com/drugs/DB13117ApprovedWithdrawnPentafluoropropane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).
Hyaluronic acid (non-animal stabilized)
go.drugbank.com/drugs/DB19175ApprovedWithdrawnHyaluronic acid (non-animal stabilized) is under investigation in clinical trial NCT03460158 (Prospective Evaluation of Facial Cosmetic Procedures).
Arbekacin
go.drugbank.com/drugs/DB06696InvestigationalAn semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexIomethin I-125
go.drugbank.com/drugs/DB20779ExperimentalIomethin I-125 is a small molecule drug. Iomethin I-125 has a monoisotopic molecular weight of 353.05 Da.
Synonyms: Iomethin i 125, Iomethin I-125ADL 10-0101
go.drugbank.com/drugs/DB05443ExperimentalADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. … Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.
XEN-2174
go.drugbank.com/drugs/DB05012ExperimentalXEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.
Upanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19